Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521756 | 0.90 | LMNA (0.61) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL12840924 | 0.88 | LMNA (0.77) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL6367942 | 0.86 | ALDH1A1 (1.00) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL29788578 | 0.86 | ALDH1A1 (1.00) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL29753282 | 0.85 | ALDH1A1 (0.78) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL29800124 | 0.85 | ALDH1A1 (0.97) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL2205195 | 0.85 | ALDH1A1 (0.97) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL17411235 | 0.84 | SIRT6 (0.81) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL520015 | 0.83 | SIRT6 (1.00) | LMNAALDH1A1SIRT6MAPTHTR6 | |
| SCHEMBL28369226 | 0.83 | ALDH1A1 (0.79) | LMNAALDH1A1SIRT6MAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | LMNA 3783/4885ALDH1A1 779/4885SIRT6 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.